Article Type
Changed
Tue, 09/25/2018 - 14:48
Display Headline
Research, innovation, and safety: Doing the right thing
Panel discussion
Article PDF
Author and Disclosure Information

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Publications
Page Number
S16-S22
Author and Disclosure Information

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Author and Disclosure Information

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Article PDF
Article PDF
Panel discussion
Panel discussion
Page Number
S16-S22
Page Number
S16-S22
Publications
Publications
Article Type
Display Headline
Research, innovation, and safety: Doing the right thing
Display Headline
Research, innovation, and safety: Doing the right thing
Citation Override
Cleveland Clinic Journal of Medicine 2007 March;74(suppl 2):S16-S22
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 07/31/2018 - 15:00
Un-Gate On Date
Tue, 07/31/2018 - 15:00
Use ProPublica
CFC Schedule Remove Status
Tue, 07/31/2018 - 15:00
Article PDF Media